XMAD
PRM
Market cap242mUSD
Oct 09, Last price
12.70EUR
1D
0.40%
1Q
-4.87%
Jan 2017
42.70%
Name
Prim SA
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Prim, S.A., operating through its various affiliated entities, specializes in the conception, production, and sale of orthopedic solutions. These items are utilized across diverse fields such as physical therapy, aquatic therapies (like thalassotherapy and hydrotherapy), rehabilitation, spa facilities, elderly care, and a range of supportive techniques, reaching customers within Spain and across global borders. Furthermore, the company supplies specialized goods for neuro-trauma, cardiovascular health, neuromodulation, surgical suites, endosurgical procedures, cosmetic surgery, and ear, nose, and throat (ENT) specialties. Beyond its product offerings, Prim, S.A. is involved in overseeing wellness developments, including hotel properties, vacation resorts, and athletic clubs. The firm was established in 1870 and maintains its principal office in Móstoles, Spain.
Related entities
Subsidiaries
ESTABLECIMIENTOS ORTOPEDICOS PRIM SA
Key people
Enrique Gimenez-Reyna Rodriguez
Second Vice Chairman of the Board · since 2018
Jose Luis Meijide Garcia
First Vice Chairman of the Board · since 2018
Esperanza Deza Anta
Chief Financial Officer
Andres Estaire Alvarez
Executive Chairman of the Board · since 2018
Carlos Velasco Iglesias
Director
Rafael Alonso Dregi
Non-Member Secretary · since 2015
Jose Ignacio Comenge
Director, Representative of La Fuente Salada, S.L.
Jorge Prim Martinez
Director · since 2018
Independent Director · since 2015
Ignacio Arraez Bertolin
Vice Secretary of the Board, Independent Director · since 2015
Headquarters & legal address
AVDA. LLANO CASTELLANO 43
Móstoles 28034
ES
Móstoles 28034
ES
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||